• Dina Rochate, Antonio Manuel González-García, Carmen Santos Marcos, Estefanía Pérez-López, Ana-África Martín-López, Mónica Alaña, Lourdes Martín Martín, Miriam López Parra, Fermín Sánchez Guijo, and Lucía López Corral.
• Hematology Department, Hospital do Divino Espírito Santo de Ponta Delgada, Ponta Delgada, Portugal.
• Medicine (Baltimore). 2024 Sep 6; 103 (36): e38659e38659.

RationaleAnti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a successful treatment for B-cell malignancies associated with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cardiovascular toxicities have also been reported in this setting. However, there is scarce data regarding development of autonomic disorders after CAR-T cell therapy.Patient ConcernsWe report a case with a patient with non-Hodgkin B-cell lymphoma, refractory to 2 prior lines of immunochemotherapy, treated with CAR-T therapy.DiagnosesOrthostatic hypotension secondary to autonomic dysfunction was diagnosed as manifestation of ICANS.InterventionsThe patient received metilprednisolone 1000 mg IV daily for 3 days and anakinra 100 mg IV every 6h.OutcomesThe vast majority of autonomic symptoms ceased and 4 months after CAR-T therapy, autonomic dysfunction was resolved.LessonsNew-onset autonomic dysfunction can occur as manifestation of ICANS in patients who experience persistent neurologic and cardiovascular symptoms after resolution of acute neurotoxicity and should be early recognized. Differences in differential diagnosis, mechanisms and treatment approaches are discussed.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

24 keywords...

hide…